Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2025)

Legend Biotech filings provide 7 years of Net Income towards Common Stockholders readings, the most recent being $2.5 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 95.76% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$261.1 million, a 30.05% increase, with the full-year FY2025 number at $33.1 million, down 82.47% from a year prior.
  • Net Income towards Common Stockholders hit $2.5 million in Q4 2025 for Legend Biotech, up from -$38.5 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $59.0 million in Q4 2024 to a low of -$199.1 million in Q2 2023.
  • Median Net Income towards Common Stockholders over the past 5 years was -$96.2 million (2021), compared with a mean of -$88.0 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 35570.18% in 2022 and later soared 40840.79% in 2024.
  • Legend Biotech's Net Income towards Common Stockholders stood at -$88.3 million in 2021, then plummeted by 53.82% to -$135.9 million in 2022, then skyrocketed by 99.89% to -$144818.0 in 2023, then soared by 40840.79% to $59.0 million in 2024, then plummeted by 95.76% to $2.5 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were $2.5 million (Q4 2025), -$38.5 million (Q3 2025), and -$124.2 million (Q2 2025) per Business Quant data.